An interventional study of Closed-loop Vibro-Tactile Stimulator and Control in Apnea Neonatal and Bradycardia Neonatal, sponsored by University of Alabama at Birmingham. Recruiting at 1 site in United States. Open to participants aged 22 Weeks to 32 Weeks. Per ClinicalTrials.gov, last updated 2026-10-02.
Sponsored by University of Alabama at Birmingham · Not applicable, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 85 studies in Apnea with a site in United States — 15 open to participants now, 18 under way, 2 of them phase 3. Apnea · United States.
Among the 85 studies in Apnea with a site in United States, this one is the 55th largest by planned enrollment of the 69 interventional ones that give a count, is one of 9 that started in 2026, is one of 49 with no phase, reaches primary completion later than 13 of the 17 other live ones, and was the 75th registered.
283 studies on the registry are indexed under Apnea; 55 are open to participants now.
Browse Apnea studies →15 of the 85 studies in Apnea with a site in United States are open now. Recruiting first, the newest first:
Pfizer · Sites in United States
Ages 18+
Pfizer · Sites in United States
Ages 18+
University of Rochester · Sites in United States
Ages 0 days–27 wk
University of North Carolina, Chapel Hill · Sites in United States
Ages 8–13 · Healthy volunteers
Indiana University · Sites in United States
Ages 18+ · Women only
A study can be open while its sites in United States have not opened yet or have stopped. Only those recruiting at a site in United States →
Of the 40 Apnea studies recruiting now, 9 (23%) set no upper age limit and 27 (68%) stop at 75 or younger; 19 take children under 18; 16 take healthy volunteers.
This study: 22 Weeks to 32 Weeks · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
85 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 4 · Phase 2 3 · Phase 3 6 · Phase 4 8
First in 1999; this study’s year is marked. 9 started in 2026.
By drug class, each counting the studies that test any of its medicines:
This study's planned enrollment of 25 is below the median of 60 across 196 interventional studies indexed under Apnea.
Median enrollment 80 across the 69 interventional studies, 113 across the 16 observational. Of the 58 that completed or were terminated, 23 (40%) have results posted.
This tab as a report to print or save as PDF → With an account.
18 of 85 have an industry lead sponsor. The 10 most frequent:
University of Alabama at Birmingham is the lead sponsor of 1,422 studies on the registry; 277 are open to participants now.
Of its 164 completed or terminated interventional studies of FDA-regulated products, 130 (79%) have results posted.
University of Alabama at Birmingham has 5 studies filed under Apnea — fewer than ten, so there is no comparison to draw.
8 of the studies in Apnea with a site in United States that are under way reach primary completion within a year, 0 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT06327152University of California, IrvineCaffeine Use in the Management of Preterm Infants | 2026-12 |
| NCT02431507Michael HarrisonMagnetic Apnea Prevention(MAGNAP) Device to Treat Obstructive Sleep Apnea:First-In-Human Study of Feasibility and Safety | 2026-12-01 |
| NCT07581938University of North Carolina, Chapel HillEarly Dental Risk Screening for Pediatric Sleep-Disordered Breathing | 2027-05 |
| NCT05527652University of MichiganSelf-Supporting Nasopharyngeal Airway (ssNPA) Treating Upper Airway Obstruction in Hypotonia | 2027-05 |
| NCT07570121Indiana UniversityPharmacokinetics and Placental Transfer of Caffeine | 2027-06 |
Add all 8 to your calendar (.ics) → With an account.
Among the 85 studies in Apnea with a site in United States, from their registry updates:
This tab as a report to print or save as PDF → With an account.
This purpose of this study is to reduce or stop apneas and bradycardias in pre-term infants, before they occur using gentle stimulation.
This will be a randomized cross-over trial that will use additional ECG leads connected to a novel device and laptop to determine the accuracy and efficacy of an algorithm to predict, detect, and interrupt episodes of bradycardia for two 4-hour periods. There will be a 4-hour period without vibro-tactile stimulation and a 4-hour period with vibro-tactile stimulation when episodes are predicted or detected.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Four hours of vibrotactile stimulation via a closed loop device if an apnea or bradycardia episode is predicted or detected.
Device: Closed-loop Vibro-Tactile Stimulator
Four hours of no vibrotactile stimulation via the closed loop device if an apnea or bradycardia episode is predicted or detected.
Device: Control
Vibro-Tactile stimulation when bradycardia is predicted or predicted.
Sham closed-loop vibrotactile stimulator
Bradycardia <100 beats per minute ≥ 10 seconds
The frequency of episodes of bradycardia (heart rate less than 100 of ≥ 10 seconds) in either study arm during the study period.
Time frame: 4-hours on either intervention.
Bradycardia <60 beats per minute ≥ 5 seconds
The frequency of episodes of bradycardia (heart rate \<60 beats per minute ≥ 5 seconds) in either study arm during the study period.
Time frame: 4 hours in either intervention.
Bradycardia <60 beats per minute ≥ 10 seconds
The frequency of episodes of bradycardia (heart rate \<60 beats per minute ≥ 10 seconds) in either study arm during the study period.
Time frame: 4 hours on either intervention.
Bradycardia <80 beats per minute ≥ 5 seconds
The frequency of episodes of bradycardia (heart rate \<80 beats per minute ≥ 5 seconds) in either study arm during the study period.
Time frame: 4 hours on either intervention.
Bradycardia <80 beats per minute ≥ 10 seconds
The frequency of episodes of bradycardia (heart rate \<80 beats per minute ≥ 10 seconds) in either study arm during the study period.
Time frame: 4 hours on either intervention.
Proportion of time with Bradycardia < 100 beats per minute
The total proportion of time with bradycardia during the study period on either intervention with a heartrate of \<100 beats per minute.
Time frame: 4 hours on either intervention.
Hypoxemia <85% for ≥ 5 seconds
The frequency of episodes of hypoxemia (oxygen saturations \<85% for ≥ 5 seconds) in either study arm during the study period.
Time frame: 4 hours on either intervention.
Hypoxemia <85% for ≥ 10 seconds
The frequency of episodes of hypoxemia (oxygen saturations \<85% for ≥ 10 seconds) in either study arm during the study period.
Time frame: 4 hours on either intervention.
Hypoxemia <90% for ≥ 5 seconds
The frequency of episodes of hypoxemia (oxygen saturations \<90% for ≥ 5 seconds) in either study arm during the study period.
Time frame: 4 hours on either intervention.
Hypoxemia <90% for ≥ 10 seconds
The frequency of episodes of hypoxemia (oxygen saturations \<90% for ≥ 10 seconds) in either study arm during the study period.
Time frame: 4 hours on either intervention.
Hypoxemia <80% for ≥ 5 seconds
The frequency of episodes of hypoxemia (oxygen saturations \<80% for ≥ 5 seconds) in either study arm during the study period.
Time frame: 4 hours on either intervention.
Hypoxemia <80% for ≥ 10 seconds
The frequency of episodes of hypoxemia (oxygen saturations \<80% for ≥ 10 seconds) in either study arm during the study period.
Time frame: 4 hours on either intervention.
Proportion of time with hypoxemia < 90%
The total proportion of time with oxygen saturations \<90% during the study period on either intervention.
Time frame: 4 hours on either intervention.
Bradycardia prediction time
The number of seconds ahead of routine patient monitors at which the device algorithm predicted bradycardia in either group.
Time frame: 4 hours on either intervention.
Bradycardia prediction accuracy
The area under the curve for the true prediction rate over the false alarm rate in the control group.
Time frame: 4 hours on sham control.
Proportion of time with hypoxemia < 85%
The total proportion of time with oxygen saturations \<85% during the study period on either intervention.
Time frame: 4 hours on either intervention.
Plan to share: Yes — Deidentified individual participant data will be made available upon publication through a data use agreement to researchers who provide a methodologically sound proposal for use in achieving the goals of the approved proposal. Proposals should be submitted to cptravers@uabmc.edu.
Supporting information: Study protocol, Statistical analysis plan
No publications or documents are linked to this record.
Started Sep 2026 (actual). Primary completion is estimated for Dec 2027, 15 months after the start.
Of 69 non-industry interventional studies with no phase under Apnea, half reached primary completion within 19 months of starting (the median), counting those still running; a quarter within 10 and three quarters within 37. This study's planned 15 months is below that.
Counting every sponsor, half of 78 studies reached it within 17 months; a quarter within 8 and three quarters within 35.
Since we started tracking on Sep 25, 2026, the dates moved once, on Oct 2, 2026: primary completion Dec 2026 → Dec 2027 and completion Dec 2027 → Dec 2028.
Earlier changes are on the record history on ClinicalTrials.gov ↗
How these figures are worked out, and which studies are left out of them.
From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗
Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.
Contact study teamGet an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
University of Alabama at Birmingham →